Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cytokinetics (CYTK)

Cytokinetics Q2 revenue rises to $66.8 million; net loss narrows to $134.4 million

Positive Impact 3 of 5 earnings Written later

Cytokinetics reported second quarter 2025 revenue of $66.8 million, up from $0.2 million a year earlier, largely from a $52.4 million Japan license recognition with Bayer. The net loss narrowed to $134.4 million, or $(1.12) per share, from $143.3 million, or $(1.31) per share, and the company maintained its full year 2025 GAAP operating expense guidance of $670 million to $710 million.

Key points

  • Total Q2 2025 revenue was $66.8 million, including $52.4 million from the Bayer Japan license and $11.7 million from clinical milestones.
  • Net loss was $134.4 million, or $(1.12) per share, versus $143.3 million, or $(1.31) per share, in Q2 2024.
  • 2025 GAAP operating expense guidance of $670 million to $710 million was maintained.
  • Cash, cash equivalents and investments were approximately $1.0 billion as of June 30, 2025, down $52.6 million in the quarter.

The filing

CompanyCytokinetics (CYTK)
Form8-K, current report
Filed with the SECAug 7, 2025, 4:01 PM ET
Accession number0000950170-25-104962

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.